Artia Global Partners LP Buys 115,000 Shares of Insmed Incorporated (NASDAQ:INSM)

Artia Global Partners LP raised its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 217.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 167,939 shares of the biopharmaceutical company's stock after purchasing an additional 115,000 shares during the quarter. Insmed accounts for about 4.1% of Artia Global Partners LP's holdings, making the stock its 11th biggest position. Artia Global Partners LP owned approximately 0.09% of Insmed worth $11,595,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in INSM. Vanguard Group Inc. raised its position in shares of Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Insmed by 1.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock valued at $877,113,000 after acquiring an additional 123,429 shares during the last quarter. Capital International Investors grew its stake in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after buying an additional 593,206 shares during the period. Geode Capital Management LLC grew its stake in shares of Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after buying an additional 273,759 shares during the period. Finally, Artisan Partners Limited Partnership grew its stake in shares of Insmed by 8.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock valued at $215,842,000 after buying an additional 242,242 shares during the period.

Insider Buying and Selling

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the completion of the sale, the chief executive officer now owns 379,534 shares of the company's stock, valued at $29,580,879.96. This trade represents a 4.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 471,797 shares of company stock worth $37,621,239. 3.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on INSM. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. UBS Group boosted their price target on Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright restated a "buy" rating and set a $90.00 price objective on shares of Insmed in a research note on Tuesday, April 22nd. Finally, Guggenheim restated a "buy" rating and set a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $94.00.

Insmed Trading Up 2.2 %

Shares of NASDAQ:INSM traded up $1.54 during midday trading on Tuesday, reaching $71.40. The company had a trading volume of 1,846,282 shares, compared to its average volume of 2,309,490. The company has a fifty day simple moving average of $74.10 and a two-hundred day simple moving average of $73.54. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market cap of $12.98 billion, a price-to-earnings ratio of -12.77 and a beta of 1.07. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.